ArticleJACC. Asia2025
Prognostic Implications of Hemoglobin Drop With and Without Overt Bleeding After Percutaneous Coronary Intervention.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough most established bleeding definitions primarily emphasize overt bleeding, endpoints from major clinical trials and studies have historically defined major bleeding to include a periprocedural hemoglobin drop of ≥3.0 g/dL. However, the clinical relevance of this laboratory-based criterion, particularly without overt bleeding, remains uncertain.
objectivesThe authors investigated the prognostic implication of a periprocedural hemoglobin drop of ≥3.0 g/dL, especially without overt bleeding.
methodsConsecutive patients were analyzed from a Japanese registry between 2008 and 2021 after percutaneous coronary intervention (PCI). Patients were classified by hemoglobin drop (≥3.0 g/dL decrease between pre- and post-PCI) and overt bleeding. Cox regression assessed associations between these groups and 2-year major adverse cardiac events (MACE, such as all-cause mortality, acute coronary syndrome, heart failure hospitalization, and stroke).
resultsAmong 7,145 patients (mean age: 69 years; 77.0% male), 73 (1.0%) had both overt bleeding and hemoglobin drop; 85 (1.2%) had overt bleeding only; 590 (8.3%) had hemoglobin drop only; and 6,397 (89.5%) had no bleeding (reference). MACE occurred in 872 (12.2%; 95% CI: 11.5-13.0) patients during the median follow-up period of 730 (Q1-Q3: 730-730) days. MACE incidence was 30.1% (95% CI: 19.9-42.0) in patients with overt bleeding and hemoglobin drop, with higher risk than those without bleeding (adjusted HR: 2.16; 95% CI: 1.37-3.42). Only those patients with hemoglobin drop were not at increased risk of MACE (adjusted HR: 1.20; 95% CI: 0.89-1.60).
conclusionsHemoglobin drop with overt bleeding after PCI was associated with increased 2-year MACE risk, whereas hemoglobin drop without overt bleeding had less prognostic relevance, highlighting the importance of clinical context in evaluating post-PCI bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.